

Piramal Glass

Story remains intact

Turnaround on track

Piramal Glass reported Q2 FY11 results, largely in line with our estimates. The story of Piramal shifting to the premium segment of the business is panning out well and it has steadily increased revenues from the premium cosmetics and perfumery (C&P). Revenues at INR3,007mn were up, marginally by 3% YoY and 8% QoQ, largely in line with our expectation of INR2911mn. PAT was reported at INR207mn (significantly above INR5mn reported in the corresponding quarter), up 25% on a QoQ, led by improving realization rates, reducing interest burden and savings from forex hedges. The company has diligently utilized operating cash flow to deleverage the balance sheet. In H1FY11, the company repaid debt of INR433mn, reducing the debt equity to 2.9x from 3.5x.

Capex on schedule

The company plans to perform the capacity transition and realignment between Q3FY11E and Q1FY12E. Earlier, we were expecting a quarter's delay, pushing the capex into FY12E. However, led by the robust demand in the C&P segment, the company now plans to execute the capex in FY11E, which will shut down production of 15% capacity for about 30-40 days. We have shifted revenues of INR275mn from FY11E to FY12E on account of the advancement of capex. Thus the PAT expectation for FY11E is being reduced by about INR42mn which is now added into the FY12E earnings.

Undervalued vis-à-vis Global peers

The company has steadily grown its premium C&P business and shifted US operations to India thus improving EBITDA margins consistently over the past 4-6 quarters. We expect the EPS for FY11E and FY12E to be INR8.6 and INR16.1 respectively. The stock is trading at 8.5x its FY12E earnings in comparison to global peers trading above 12x despite lower competitive advantage and reducing market share. Subsequently, we maintain our **'Buy'** rating and reiterate our target price of INR186 per share.

Rating : Buy

Target Price : INR186

Upside : 36%

CMP : INR136 (as on 28 October 2010)


Key data*

Bloomberg /Reuters Code	PIRA IN/PRML.BO
Current /Dil. Shares O/S (mn)	80/80
Mkt Cap (INRbn/US\$mn)	11.0 /246.4
Daily Vol. (3M NSE Avg.)	136,447
Face Value (INR)	10

1 US\$= INR 44.5

Source: Bloomberg; * As on 28 October 2010

Price & Volume



Source: Bloomberg

Share holding (%)	Q3FY10	Q4FY10	Q1FY11	Q2FY11
Promoter	76.8	76.8	76.8	72.7
Institutional Investors	0.1	0.1	0.1	5.8
Other Investors	11.1	11.1	11.8	10.0
General Public	12.1	12.0	11.4	11.5

Source: Bloomberg

Price performance (%)	3M	6M	12M
Sensex	11.0	14.7	22.5
Piramal Glass	22.8	47.7	181.2

Source: Bloomberg

Y/E March (INR mn)	Q2FY11	Q2FY10	YoY(%)	Q1FY11	QoQ (%)	Q2FY11E	Variance (%)
Net Sales	3,007	2,928	2.7	2,783	8.0	2,911	3.3
Operating Expenses	2,361	2,431	(2.9)	2,218	6.4	2,358	0.1
% of Sales	78.5	83.0	(5.4)	79.7	(1.5)	81.0	(3.1)
EBITDA	646	497	29.8	565	14.2	553	16.8
EBITDA Margins (%)	21.5	17.0	26.4	20.3	5.8	19.0	13.1
Depreciation	231	229	1.2	229	1.1	229	1.1
Interest	171.2	309.8	(44.7)	169.8	0.8	204	(16.0)
PBT	304	20	1,387.7	207	46.4	181	68.1
Tax	69	15	372.1	32	118.2	-	-
Effective Tax Rate (%)	22.9	72.1	(68.3)	15.3	49.1	-	-
PAT before Minority	234	6	4,007.0	176	33.4	181	29.7
NPM (%)	7.8	0.2	3,899.8	6.3	23.5	6.2	25.6
PAT after Minority	207	5	3,727.8	165	25.3	170	21.8
EPS	2.6	0.2	1,411.7	2.2	17.9	2.1	21.8

Source: Company, Elara Securities Estimate

Key Financials	Y/E Mar (INR mn)	Rev	YoY (%)	EBITDA	EBITDA (%)	Rep PAT	YoY (%)	Fully DEPS	RoE (%)	RoCE (%)	P/E (x)	EV/EBITDA (x)
FY08	7,786	11.1	1,017	13.1	(228)	(41.5)	(12.7)	(0.1)	0.0	(10.7)	20.4	
FY09	10,088	29.6	1,279	12.7	(1,026)	349.2	(44.5)	(116.4)	(1.1)	(3.1)	16.3	
FY10	11,039	9.4	2,160	19.6	44	(104.3)	0.8	1.6	7.2	162.4	9.6	
FY11E	11,608	5.2	2,380	20.5	694	1,465.7	8.6	19.5	10.5	15.8	8.7	
FY12E	13,273	14.3	3,205	24.2	1,296	86.8	16.1	26.0	15.5	8.5	6.5	


Source: Company, Elara Securities Estimate

Consolidated Financials (Y/E Mar)

Income Statement (INR mn)	FY09	FY10	FY11E	FY12E
Net Revenues	10,088	11,039	11,608	13,273
Operating EBITDA	1,279	2,160	2,380	3,205
Less:- Forex exp	540	339	97	140
OPBITDA	739	1,822	2,283	3,065
Less :- Depreciation & Amortization	892	907	921	973
EBIT	(153)	915	1,362	2,092
Less:- Interest exp	1314	1049	690	599
Add Other income	209	221	221	221
PBT	(1,258)	87	893	1,714
Less :- Taxes	(186)	54	101	291
PAT	(1,072)	32	792	1,422
Add/Less: - Minority Interests	(47)	(12)	98	127
PAT after minority	(1,026)	44	694	1,296
Balance Sheet (INR mn)	FY09	FY10	FY11E	FY12E
Share Capital	180	804	804	804
Reserves	254	1,595	2,288	3,584
Minority Interest	447	376	474	601
Borrowings	13,571	9,824	9,324	8,424
Deferred Tax (Net)	93	113	113	113
Total Liabilities	14,544	12,713	13,004	13,527
Gross Block	14,052	13,673	14,673	15,273
Less:- Accumulated Depreciation	4,490	5,252	6,173	7,146
Net Block	9,562	8,421	8,500	8,126
Add:- Capital work in progress	148	141	141	141
Investments	1	1	1	1
Net Working Capital	4,833	4,150	4,363	5,258
Other Assets	0	-	-	-
Total Assets	14,545	12,713	13,004	13,527
Cash Flow Statement (INR mn)	FY09	FY10	FY11E	FY12E
Cash profit adjusted for non cash items	940	2,008	2,403	2,995
Add/Less : Working Capital Changes	(1,192)	573	(23)	(211)
Operating Cash Flow	(253)	2,580	2,380	2,784
Less:- Capex	(1,645)	(244)	(1,000)	(600)
Free Cash Flow	(1,897)	2,337	1,380	2,184
Financing Cash Flow	1,832	(2,352)	(1,190)	(1,499)
Investing Cash Flow	(1,547)	(208)	(1,000)	(600)
Net change in Cash	32	21	190	685
Ratio Analysis	FY09	FY10	FY11E	FY12E
Income Statement Ratios(%)				
Revenue Growth	29.6	9.4	5.2	14.3
EBITDA Growth	25.7	68.9	10.2	34.7
PAT Growth	369.6	(103.0)	2,347.9	79.7
EBITDA Margin	12.7	19.6	20.5	24.2
Net Margin	(10.6)	0.3	6.8	10.7
Return & Liquidity Ratios				
Net Debt/Equity (x)	15.3	3.5	2.5	1.5
ROE (%)	(116.4)	1.6	19.5	26.0
ROCE (%)	(1.1)	7.2	10.5	15.5
Per Share data & Valuation Ratios				
Diluted EPS (INR/Share)	(44.5)	0.8	8.6	16.1
EPS Growth (%)	NA	NA	926.9	86.8
DPS (INR/Share)	0.0	0.0	0.0	0.0
P/E Ratio (x)	(3.1)	162.4	15.8	8.5
EV/EBITDA (x)	16.3	9.6	8.7	6.5
EV/Sales (x)	2.1	1.9	1.8	1.6
Price/Book (x)	25.3	4.6	3.5	2.5
Dividend Yield (%)	-	-	-	-


Source: Company, Elara Securities Estimates

Revenue & margins growth trend




Source: Company, Elara Securities Estimates

Adjusted profits growth trend



Source: Company, Elara Securities Estimates

Return ratios



Source: Company, Elara Securities Estimates


Story remains intact

Turnaround on track

Piramal Glass reported Q2 FY11 results, largely in line with our estimates. The story of Piramal shifting to the premium segment of the business is panning out well and it has steadily increased the premium cosmetics and perfumery (C&P) revenues.

Revenues at INR3,007mn have grown marginally by 3% YoY and 8% QoQ, largely in line with our expectation of INR2911mn. The glass business operates at full utilizations, and has minimal volume growth opportunity. But Piramal Glass continues to transform the product mix from low-end pharma and food and beverage segment to premium C&P segment, garnering better realization rates.

Exhibit 1: Revenue mix



Source: Company

Piramal Glass has sustained the improvement in EBITDA margins at 21.5%, an improvement of 350bps YoY and 120bps QoQ. Higher realization rates have directly flowed into the profitability. Subsequently, Piramal has refrained from taking longer term complex forex bets, enabling it to mitigate losses seen in the past. PAT has been reported at INR207mn, significantly above the INR5mn reported in the corresponding quarter while it showed a 25% growth on QoQ. Apart from the EBITDA margin improvement, reduction in interest burden played a key role in reducing interest expenses by 45% on YoY due to the decreasing interest cost and debt burden.

Capex on schedule

Piramal Glass is witnessing a serious traction from the C&P segment, and has been maintaining its strategy of shifting capacities from low demand pharma to C&P segment. The company plans to perform the capacity transition and realignment between Q3 FY11E and Q1FY12E. Earlier, we were expecting a quarter's delay, pushing the capex into FY12E. However, led by the robust demand in the C&P segment, the company now

plans to execute the capex in FY11E, which will shut down production of 15% capacity for about 30-40 days.

This will reduce the sales volume in the current fiscal on account of lower production days though it remains in the interest of the company's strategy to scale up the premium C&P segment - which will translate into higher earnings in FY12E.

Exhibit 2: Capex plan

Segment	Current Capacity*	Expected Capacity*	Timeline	capacity shut down
Pharma	75	65	Q3FY11-Q1FY12	30 days
C&P	25	40	Q3FY11-Q1FY12	40-60 days
C&P	65	95	Q3FY11-Q1FY12	40-60 days


*Tonnes per day

Source: Company

Robust outlook

The company has steadily grown its premium C&P business and shifted US operations to India thus improving EBITDA margins consistently over the past 4-6 quarters. We believe that the company has gained a strong foothold in the premium C&P segment while the demand looks robust with about 150 new products in the pipeline. Being the sole Asian player in the business, the company has a limited competitive threat.

Exhibit 3: Revenues Estimations (INR mn)



Source: Company, Elara Securities

Deleveraging under process

On the balance sheet front, the company is strengthening its liquidity position. It is diligently utilizing the operating cash flow to deleverage the balance sheet. In the last two quarters, the company has repaid debt of INR433mn, reduced the debt equity to 2.9x from 3.5x in Q1FY11. This has enabled Piramal Glass to reduce its interest cost to about 7.25%. This is expected to move down further by 50bps and cut down the interest expense significantly.

Undervalued vis-à-vis Global peers

We have reduced our FY11E revenue estimates by INR275mn and shifted it to FY12E on account of the advancement of capex. Thus FY11E PAT expectation is being reduced by about INR42mn which has largely added on to the FY12E earnings. We expect FY11E and FY12E EPS of INR8.6 and INR16.1 respectively. The stock is trading at 8.5x its FY12E earnings in comparison to global peers trading above 12x despite lower competitive advantage and reducing market share. Subsequently, we maintain our Buy rating and reiterate our target price of INR186 per share.


Exhibit 4: Valuation Summary

EV/EBITDA Based Valuation	INRmn
Operating EBITDA*	3,205
Target Multiple assigned (x)	7.0
Enterprise Value	22,438
Net Debt	7,478
Market Cap	14,960
No of Diluted shares (mn)	80.4
Target Price (INR)	186.0
Upside (%)	36.4

* Excluding forex gains/losses

Source: Elara Securities

Coverage History



Date	Rating	Target Price	Closing Price
1 3-Sep-2010	Buy	INR186	INR132

Guide to Research Rating

BUY	Absolute Return >+20%
ACCUMULATE	Absolute Return +5% to +20%
REDUCE	Absolute Return -5% to +5%
SELL	Absolute Return < -5%

Disclosures & Confidentiality

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara is under no obligation to update or keep the information current. Neither Elara nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited / the company.

Disclaimer

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

India
Elara Securities (India) Pvt. Ltd.
 Kalpataru Synergy, 6th Level,
 East Wing, Opp Grand Hyatt,
 Santacruz East,
 Mumbai – 400 055, India
 Tel : +91 22 4062 6868

Europe
Elara Capital Plc.
 29 Marylebone Road,
 London NW1 5JX,
 United Kingdom
 Tel : +44 20 7486 9733

USA
Elara Capital Inc.
 535 Fifth Avenue
 29th Floor
 New York, NY 10017
 Tel : 646-884-7130

Asia / Pacific
Elara Capital (Singapore) Pte. Ltd.
 30 Raffles Place
 #20-03, Chevron House
 Singapore 048622
 Tel : +65 6536 6267

Harendra Kumar **Head - Institutional Equities & Global Research** harendra.kumar@elaracapital.com +91 22 4062 6871

Sales

Joseph K. Mammen **Global Head Sales & Trading**
 London +44 78 5057 7329 joseph.mammen@elaracapital.com +44 20 7467 5578

Jonathan Camissar London +44 79 1208 7272 jonathan.camissar@elaracapital.com +44 20 7299 2575

Vishal Pattani London +44 77 0220 1384 vishal.pattani@elaracapital.com +44 20 7467 5452

Prashin Lalvani India +91 98334 77685 prashin.lalvani@elaracapital.com +91 22 4062 6844

Koushik Vasudevan India +91 98676 96668 koushik.vasudevan@elaracapital.com +91 22 4062 6841

Amit Mamgain India +91 98676 96661 amit.mamgain@elaracapital.com +91 22 4062 6843

Nirav Shah India +91 90040 27862 nirav.shah@elaracapital.com +91 22 4062 6842

Sales Trading & Dealing

Ananthanarayan Iyer India +91 98334 99217 ananthanarayan.iyer@elaracapital.com +91 22 4062 6856

Vishal Thakkar India +91 98694 07973 vishal.thakkar@elaracapital.com +91 22 4062 6857

Manoj Murarka India +91 99675 31422 manoj.murarka@elaracapital.com +91 22 4062 6851

Research

Abhinav Bhandari Analyst Construction, Infrastructure abhinav.bhandari@elaracapital.com +91 22 4062 6807

Aliasgar Shakir Analyst Mid caps aliasgar.shakir@elaracapital.com +91 22 4062 6816

Alok Deshpande Analyst Oil & Gas alok.deshpande@elaracapital.com +91 22 4062 6804

Amol Bhutada Analyst Auto & Auto Ancillaries amol.bhutada@elaracapital.com +91 22 4062 6806

Himani Singh Analyst FMCG, Hotels, Hospitals himani.singh@elaracapital.com +91 22 4062 6801

Mohan Lal Analyst Media & Retail mohan.lal@elaracapital.com +91 22 4062 6802

Pankaj Balani Analyst Derivative Strategist pankaj.balani@elaracapital.com +91 22 4062 6811

Pralay Das Analyst Information Technology pralay.das@elaracapital.com +91 22 4062 6808

Ravindra Deshpande Analyst Metals & Cement ravindra.deshpande@elaracapital.com +91 22 4062 6805

Ravi Sodah Analyst Cement ravi.sodah@elaracapital.com +91 22 4062 6817

Satyender Khatter Analyst Banking & Telecom satyender.khatter@elaracapital.com +91 22 4062 6809

Sumant Kumar Analyst FMCG sumant.kumar@elaracapital.com +91 22 4062 6803

Surajit Pal Analyst Pharmaceuticals, Real Estate surajit.pal@elaracapital.com +91 22 4062 6810

Kavitha Rajan Associate Telecom, Information Technology kavitha.rajan@elaracapital.com +91 22 4062 6814

Pooja Sharma Associate Construction, Infrastructure pooja.sharma@elaracapital.com +91 22 4062 6819

Saira Ansari Associate Pharmaceuticals, Real Estate saira.ansari@elaracapital.com +91 22 4062 6812

Sreevalsan Menon Editor sreevalsan.menon@elaracapital.com +91 22 4062 6813

Gurunath Parab Production gurunath.parab@elaracapital.com +91 22 4062 6815

Access our reports on Bloomberg: Type **ESEC <GO>**

Also available on **Thomson & Reuters**

Member (NSE, BSE)
 Regn Nos: CAPITAL MARKET SEBI REGN. NO.: BSE: INB 011289833, NSE: INB 231289837 DERIVATIVES SEBI REGN. NO.: NSE: INF 231289837
 CLEARING CODE: M51449.
 Website: www.elaracapital.com Investor Grievance Email ID: investor.grievances@elaracapital.com